Exelixis Inc. (EXEL)
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EXEL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $15.77B
- P/E (TTM)
- 19.35
- Forward P/E
- 15.12
- EPS (TTM)
- $3.34
- Dividend yield
- None
- 52-week range
- 39.71 – 73.69
- Day range
- 64.45 – 66.94
- Volume / Avg
- 2.19M / 2.45M
- Beta
- —
- Shares outstanding
- 244.01M
52-week range
EXEL stock today
Shares of Exelixis (EXEL) finished lower on Nov 20 at $64.63, a drop of 1.82% or $1.20 per share, versus the S&P 500's 3.70% decline. At this level, EXEL sits in the middle of its 52-week range of $39.71 to $73.69: 12.3% below the high, set on Nov 5, 2026 and 62.8% above the low. EXEL is up 47.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 52.0%.
At 19.4x trailing earnings, Exelixis trades below the peer-group median of 26.6x. Its forward P/E of 15.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Exelixis
Company profileExelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Michael M. Morrissey Ph.D.
- Headquarters
- Alameda, CA
- Employees
- 1,077
- IPO year
- 2000
- Website
- exelixis.com
Financial highlights
Full financialsIn fiscal 2025, Exelixis generated $2.32 billion in revenue, up 7.0% from fiscal 2024, its 9th consecutive year of revenue growth. Net income was $782.6 million (+50.1% year over year), for a net margin of 33.7% versus a median of 11.4% in the prior 5 years. Gross margin was 96.4% (down from 96.5%) and operating margin 37.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Growth | +6.98% | +18.49% | +13.60% | +12.27% | +45.31% |
| Net income | $782.57M | $521.27M | $207.76M | $182.28M | $231.06M |
| EPS (diluted) | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
Analyst forecast
ForecastConsensus (17 analysts)
buy
Avg. price target
$61.57-4.73%
- Strong buy 1
- Buy 5
- Hold 10
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $0.85 vs $0.79
- Surprise
- +7.59%
EXEL news
All EXEL news- Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?Nasdaq
- Exelixis: Management's $5 Billion Aspiration Is Already In The Share PriceSeeking Alpha
- Exelixis Eyes Q1 Zanza Data as It Plans Beyond CABONasdaq
- Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha
- Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change EverythingNasdaqEXEL, BIO.B
- Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.NasdaqEXEL, PFE
- XBI, SYRE, EXEL, BIIB: ETF Outflow AlertNasdaqXBI, SYRE, EXEL, BIIB
Exelixis peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NBIXNeurocrine Biosciences Inc. | 150.57 | -3.84% | $15.24B | vs EXEL |
| BNTXBioNTech SE ADR | 80.96 | -0.52% | $20.07B | vs EXEL |
| TECHBio-Techne Corp | 72.67 | -0.04% | $11.42B | vs EXEL |
| RGENRepligen Corporation | 163.81 | -3.81% | $10.47B | vs EXEL |
| HALOHalozyme Therapeutics Inc. | 91.35 | -1.82% | $10.41B | vs EXEL |
| QGENQiagen N.V. | 49.30 | -0.66% | $10.18B | vs EXEL |
| KYMRKymera Therapeutics Inc. | 115.31 | -3.42% | $9.84B | vs EXEL |
| KRYSKrystal Biotech Inc. | 308.89 | -2.19% | $9.15B | vs EXEL |
Indexes, lists and sector
Exelixis stock FAQ
What is Exelixis's stock price today?
EXEL last traded at $64.63 as of Nov 20, 4:00 PM EST, down 1.82% on the day. Prices are delayed at least 15 minutes.
What is EXEL's P/E ratio?
EXEL trades at a trailing P/E ratio of 19.35 and a forward P/E of 15.12, compared with a median of 26.6 for its closest peers.
Who is Exelixis's CEO?
Dr. Michael M. Morrissey Ph.D. is the chief executive officer of Exelixis Inc., which has about 1,077 employees.
What is the EXEL 52-week high?
The 52-week high for EXEL is $73.69 and the 52-week low is $39.71. The stock is currently 12.3% below its high.